Exciting Advances in Hearing Loss Treatment

It’s truly remarkable news.

About 11 million people in the U.S. believe they are deaf or have significant hearing difficulties.

While no medications currently exist to tackle hereditary hearing loss, cochlear implants can assist individuals by bypassing damaged parts of the inner ear and directly stimulating the auditory nerves.

Recently, new gene therapy injections have sparked hope, successfully restoring hearing in individuals with mutations in the OTOF gene.

Researchers introduced an AAV vector carrying a healthy version of the OTOF gene into the inner ears of 10 patients, ranging from 1 to 24 years old.

The OTOF gene is crucial as it encodes otoferlin, a protein vital for relaying sound signals from the ear to the brain.

When these genes aren’t functioning, the necessary connection between hair cells in the inner ear and the auditory nerves suffers a disruption.

Participants began noticing improvements in their hearing within a month. Remarkably, the average threshold for recognizable sounds decreased from 106 decibels (comparable to a lawn mower or motorcycle) to around 52 decibels, which is typical for normal conversation, within just six months.

Interestingly, younger participants, particularly those aged 5 to 8, showed notable responses.

In one unexpected instance, a 7-year-old girl was nearly able to regain her full hearing and engage in conversation with her mother merely four months post-treatment.

Maori Duan, a consultant in the Department of Clinical Science, Intervention, and Technology at the Karolinska Institute in Sweden, expressed, “This is a huge step forward in genetic treatment of hearing loss. It can change lives for children and adults.”

Duan noted that while small studies in China had previously shown favorable outcomes for children, this is the first time such a method was examined in teenagers and adults.

The treatment has shown to be well-received, with no serious side effects observed during a follow-up period of 6 to 12 months.

The most common reaction involved a temporary dip in neutrophil counts, a type of white blood cell.

“Many participants can experience significant improvements in their hearing, which can dramatically affect their quality of life,” Duan remarked. “We’re going to monitor these patients to see how lasting the effects are.”

He also emphasized that the OTOF gene is “just the beginning.” Researchers are now looking into other prevalent genes that contribute to hearing loss, such as GJB2 and TMC1.

These cases are more challenging to address, yet animal studies have yielded encouraging results thus far. There is optimism that eventually, individuals with various forms of genetic hearing loss will have access to treatments.